Eligibility for PCSK9 Inhibitors According to American College of Cardiology (ACC) and European Society of Cardiology/European Atherosclerosis Society (ESC/EAS) Guidelines After Acute Coronary Syndromes

BACKGROUND: The American College of Cardiology (ACC) and European Society of Cardiology/European Atherosclerosis Society (ESC/EAS) have recently published recommendations for the use of proprotein convertase subtilisin/kexin‐9 (PCSK9) inhibitors in situations of very high risk. We aim to assess in t...

Descripción completa

Detalles Bibliográficos
Autores principales: Gencer, Baris, Koskinas, Konstantinos C., Räber, Lorenz, Karagiannis, Alexios, Nanchen, David, Auer, Reto, Carballo, David, Carballo, Sebastian, Klingenberg, Roland, Heg, Dik, Matter, Christian M., Lüscher, Thomas F., Rodondi, Nicolas, Mach, François, Windecker, Stephan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2017
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5721754/
https://www.ncbi.nlm.nih.gov/pubmed/29122809
http://dx.doi.org/10.1161/JAHA.117.006537

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5721754/
https://www.ncbi.nlm.nih.gov/pubmed/29122809
http://dx.doi.org/10.1161/JAHA.117.006537

Ejemplares similares